Impact of gut microbiota on severity of obsessive-compulsive disorder (OCD) - a short review
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.028Keywords
Obsessive-Compulsive Disorder, Gut Microbiota, Gut-Brain Axis, ProbioticsAbstract
Introduction and purpose
Obsessive-compulsive disorder (OCD) has an unclear etiology. Genetic and environmental factors dominate among the etiologic factors. The disorder is characterized by the presence of obsessions (repetitive and persistent thoughts, images, impulses or urges) and compulsions (rituals; repetitive behaviours or mental acts that the individual feels driven to perform in response to an obsession). This disorder has less than 4% of the population. Treatment is a long and difficult process, and the best results are with SSRIs (e.g., fluoxetine) and cognitive behavioral therapy (CBT). The aim of the study was to review articles linking gut microbiota and obsessive-compulsive disorder issues.
A brief description of the state of knowledge
The gut microbiota-gut-brain axis perhaps has an impact on the etiology of psychiatric diseases. Its existence has been well researched in animals. Researches suggest that there possibly may be changes in the composition of the gut microbiota in people with obsessive-compulsive disorder. Quantitative and qualitative changes in the gut microbiota composition may worsen the patient's condition. The use of probiotics may help improve the patient's condition and reduce symptoms of the disorder.
Summary (conclusions)
More research is needed to explore the potential impact of the gut microbiota on obsessive-compulsive disorder. This could perhaps lead to future applications of probiotics, e.g., in the adjunctive treatment of obsessive-compulsive disorder.
References
Nazeer A, Latif F, Mondal A, Azeem MW, Greydanus DE. Obsessive-compulsive disorder in children and adolescents: epidemiology, diagnosis and management. Transl Pediatr. 2020;9(Suppl 1):S76-S93. doi:10.21037/tp.2019.10.02
Leckman JF, Denys D, Simpson HB, et al. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010;27(6):507-527. doi:10.1002/da.20669
Smit DJA, Cath D, Zilhão NR, et al. Genetic meta-analysis of obsessive-compulsive disorder and self-report compulsive symptoms. Am J Med Genet B Neuropsychiatr Genet. 2020;183(4):208-216. doi:10.1002/ajmg.b.32777
Stein DJ, Kogan CS, Atmaca M, et al. The classification of Obsessive-Compulsive and Related Disorders in the ICD-11. J Affect Disord. 2016;190:663-674. doi:10.1016/j.jad.2015.10.061
Guzick AG, Candelari A, Wiese AD, Schneider SC, Goodman WK, Storch EA. Obsessive-Compulsive Disorder During the COVID-19 Pandemic: a Systematic Review. Curr Psychiatry Rep. 2021;23(11):71. doi:10.1007/s11920-021-01284-2
Skapinakis P, Caldwell DM, Hollingworth W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016;3(8):730-739. doi:10.1016/S2215-0366(16)30069-4
Fineberg NA, Baldwin DS, Drummond LM, et al. Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder. Int Clin Psychopharmacol. 2018;33(6):334-348. doi:10.1097/YIC.0000000000000237
Del Casale A, Sorice S, Padovano A, et al. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD). Curr Neuropharmacol. 2019;17(8):710-736. doi:10.2174/1570159X16666180813155017
Marsden Z, Lovell K, Blore D, Ali S, Delgadillo J. A randomized controlled trial comparing EMDR and CBT for obsessive-compulsive disorder. Clin Psychol Psychother. 2018;25(1):e10-e18. doi:10.1002/cpp.2120
Zhou DD, Zhou XX, Li Y, et al. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2019;90:277-287. doi:10.1016/j.pnpbp.2018.12.009
Morais LH, Schreiber HL 4th, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021;19(4):241-255. doi:10.1038/s41579-020-00460-0
Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-209
Dinan TG, Cryan JF. Brain-Gut-Microbiota Axis and Mental Health. Psychosom Med. 2017;79(8):920-926. doi:10.1097/PSY.0000000000000519
Mörkl S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the Microbiota-Gut-Brain Axis: Focus on Psychiatry. Curr Nutr Rep. 2020;9(3):171-182. doi:10.1007/s13668-020-00313-5
Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021;160(5):1486-1501. doi:10.1053/j.gastro.2020.10.066
Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep. 2017;17(12):94. doi:10.1007/s11910-017-0802-6
Generoso JS, Giridharan VV, Lee J, Macedo D, Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry. 2021;43(3):293-305. doi:10.1590/1516-4446-2020-0987
Turna J, Grosman Kaplan K, Anglin R, et al. The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study. Acta Psychiatr Scand. 2020;142(4):337-347. doi:10.1111/acps.13175
Domènech L, Willis J, Alemany-Navarro M, et al. Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder. Sci Rep. 2022;12(1):1448. doi:10.1038/s41598-022-05480-9
Kilinçarslan S, Evrensel A. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with inflammatory bowel disease: an experimental study. Actas Esp Psiquiatr. 2020;48(1):1-7.
Kantak PA, Bobrow DN, Nyby JG. Obsessive-compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG). Behav Pharmacol. 2014;25(1):71-79. doi:10.1097/FBP.0000000000000013
Kobliner V, Mumper E, Baker SM. Reduction in Obsessive Compulsive Disorder and Self-Injurious Behavior With Saccharomyces boulardii in a Child with Autism: A Case Report. Integr Med (Encinitas). 2018;17(6):38-41.
Tao D, Zhong T, Pang W, Li X. Saccharomyces boulardii improves the behaviour and emotions of spastic cerebral palsy rats through the gut-brain axis pathway. BMC Neurosci. 2021;22(1):76. doi:10.1186/s12868-021-00679-4
Sanikhani NS, Modarressi MH, Jafari P, et al. The Effect of Lactobacillus casei Consumption in Improvement of Obsessive-Compulsive Disorder: an Animal Study. Probiotics Antimicrob Proteins. 2020;12(4):1409-1419. doi:10.1007/s12602-020-09642-x
D'Addario C, Pucci M, Bellia F, et al. Regulation of oxytocin receptor gene expression in obsessive-compulsive disorder: a possible role for the microbiota-host epigenetic axis. Clin Epigenetics. 2022;14(1):47. doi:10.1186/s13148-022-01264-0
Murphy TK, Brennan EM, Johnco C, et al. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol. 2017;27(7):640-651. doi:10.1089/cap.2016.0190
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Kacper Niewęgłowski, Natalia Wilczek, Michał Rycharski, Julita Niewęgłowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 917
Number of citations: 0